Jacobs Levy Equity Management Inc. Has $4.65 Million Stock Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Jacobs Levy Equity Management Inc. trimmed its position in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 1.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 576,447 shares of the biopharmaceutical company’s stock after selling 10,167 shares during the quarter. Jacobs Levy Equity Management Inc. owned about 1.18% of Theravance Biopharma worth $4,646,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. BNP Paribas Financial Markets lifted its position in Theravance Biopharma by 88.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company’s stock worth $2,462,000 after acquiring an additional 143,781 shares during the last quarter. Marshall Wace LLP increased its stake in shares of Theravance Biopharma by 83.6% in the second quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company’s stock worth $2,523,000 after purchasing an additional 135,426 shares during the period. Squarepoint Ops LLC acquired a new position in shares of Theravance Biopharma during the 2nd quarter worth about $986,000. Algert Global LLC bought a new stake in Theravance Biopharma during the 3rd quarter valued at approximately $851,000. Finally, Bank of Montreal Can boosted its stake in Theravance Biopharma by 141.0% during the 2nd quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company’s stock valued at $1,414,000 after purchasing an additional 93,702 shares during the period. 99.10% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

TBPH has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Theravance Biopharma in a report on Monday, September 16th. StockNews.com downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $13.75.

Insider Buying and Selling

In related news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now owns 322,743 shares of the company’s stock, valued at $2,904,687. The trade was a 1.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 6.90% of the company’s stock.

Theravance Biopharma Trading Up 0.4 %

TBPH opened at $9.88 on Friday. The stock has a market cap of $485.80 million, a PE ratio of -9.78 and a beta of 0.23. Theravance Biopharma, Inc. has a 1 year low of $7.44 and a 1 year high of $11.71. The stock’s 50 day simple moving average is $8.86 and its 200-day simple moving average is $8.72.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.16). The business had revenue of $16.87 million during the quarter, compared to the consensus estimate of $16.11 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. During the same period last year, the firm earned ($0.17) EPS. Equities analysts forecast that Theravance Biopharma, Inc. will post -1.06 earnings per share for the current fiscal year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.